Expertise in
6
conditions

Dr. Eneida R. Nemecek

Hematology | Oncology
OHSU Hospital
3181 SW Sam Jackson Park Rd, 
Portland, OR 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
24 Years of Experience
Expertise in
6
conditions
OHSU Hospital
3181 SW Sam Jackson Park Rd, 
Portland, OR 

Overview

Eneida Nemecek is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. She has been practicing medicine for over 24 years.

Dr. Nemecek is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 62 peer reviewed articles and participating in 10 clinical trials. Dr. Nemecek is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in OR

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

BridgeSpan
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
View 1 Less Insurance Carrier -

Locations

OHSU Hospital
3181 SW Sam Jackson Park Rd, Portland, OR 97239

Additional Areas of Focus

Dr. Nemecek has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological
Study Phase: Phase 2
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Tacrolimus, Methotrexate
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 20, 2024
Intervention Type: Drug, Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Enrollment Status: Unknown
Publish Date: December 05, 2023
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Enrollment Status: Completed
Publish Date: March 17, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Biological
Study Phase: Phase 2
View 9 Less Clinical Trials

62 Total Publications

Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.
Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2026
Similar Doctors
Expertise in
5
conditions
Dr. Michael P. Recht
Hematology | Oncology
Expertise in
5
conditions
Dr. Michael P. Recht
Hematology | Oncology
Referral may be required

Doernbecher Children's Hospital

700 SW Campus Dr, 
Portland, OR 
 (0.2 miles away)
503-494-8716
Languages Spoken:
English
See accepted insurances

Michael Recht is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Recht is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, Glanzmann Thrombasthenia, and Endoscopy.

Expertise in
8
conditions
Dr. Hagen F. Kennecke
Hematology | Oncology
Expertise in
8
conditions
Dr. Hagen F. Kennecke
Hematology | Oncology
Referral may be required

Providence Cancer Institute Franz Clinic

4805 NE Glisan St Ste 11N-1, 
Portland, OR 
 (5.0 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hagen Kennecke is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Kennecke is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Carcinoid Syndrome. Dr. Kennecke is currently accepting new patients.

Expertise in
4
conditions
Dr. Stephen S. Roberts
Hematology | Oncology
Expertise in
4
conditions
Dr. Stephen S. Roberts
Hematology | Oncology
Referral may be required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (0.1 miles away)
503-494-1543
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Roberts is a Hematologist and an Oncologist practicing medicine in Portland, Oregon. Dr. Roberts is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Hereditary Neuroblastoma. Dr. Roberts is currently accepting new patients.

Frequently Asked Questions about Dr. Eneida R. Nemecek

How do I make an appointment with Dr. Eneida R. Nemecek?

You can book an appointment with Dr. Eneida R. Nemecek by calling their office at 503-494-0829. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Eneida R. Nemecek a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Eneida R. Nemecek is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Eneida R. Nemecek specialize in?

While Dr. Eneida R. Nemecek is a Hematology, they have specific expertise in Multiple Myeloma, Graft Versus Host Disease (GvHD), and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Eneida R. Nemecek participate in research or clinical trials?

Yes. Dr. Eneida R. Nemecek has published 62 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Eneida R. Nemecek's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Eneida R. Nemecek accept my insurance?

Dr. Eneida R. Nemecek accepts most major insurance plans, including BridgeSpan and Coordinated Care. We recommend calling the office directly at 503-494-0829 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nemecek's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile